BioAssets: Convergence as Marketing Play

Most drug and device companies approach convergence as a product development issue--the actual combination in a single product of both device and pharmaceutical attributes. But what if convergence were played out as part of a marketing strategy? That's one of the possibilities being explored by BioAssets, a drug company with a novel approach to the use of TNF inhibitors in spine, who hopes to tap into the strong customer relationships that spine device companies have with surgeons.

If the current controversy about drug-eluting stent safety proves anything—the nervous debate whether, according to a number of clinical studies reported this fall, drug-eluting stents (DES) lead to higher thrombosis rates than bare metal stents—it’s that, from a product development point of view, the combination of drugs and device technology may be even more difficult than many people—especially device executives--anticipated. Particularly where DES are concerned, most device companies—who have led the charge in true drug/device convergence—sought to mitigate the inherent pharma risk of convergence by using compounds already on the market, focusing instead on refining the traditional device attributes, such as ease of use and delivery, of their combination products. The emergence downstream of reports of higher incidence of thrombosis years after implantation of the stent is the kind of safety risk that pharmaceutical companies routinely prepare themselves for, but that device companies rarely do—the safety and efficacy of most devices are matters of procedural success and therefore known almost immediately. For this reason alone, the safety controversy has huge implications not just for DES themselves, but for device companies pursuing convergence strategies more broadly, raising the fundamental question: can device firms truly mitigate risk when pursuing drug/device combinations? (See "At TCT, DES Use and Safety Concerns: Irrational Exuberance or Irrational Anxiety?" IN VIVO, November 2006. Also see "At TCT, DES Use and Safety Concerns: Irrational Exuberance or Irrational Anxiety?" - In Vivo, 1 November, 2006.)

But risk mitigation in most convergence categories is almost entirely a matter of product development. What if drug/device convergence—the combination in somewhat equal measures of drug and device components—were more...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.